OKLAHOMA Health Care Authority	
Health Care Authority	

State of Oklahoma SoonerCare





Phesgo[™] (Pertuzumab/Trastuzumab/Hyaluronidase-zzxf) **Prior Authorization Form**

	-					
Member Name:	Date	e of Birth:	Member ID#:			
Drug Information						
□Physician billing (HCPC	CS code:	_) ❑Pharmacy	billing (NDC:)		
Dose:	Regimen:	Stal	rt Date (or date of next dose):			
Billing Provider Information						
Provider NPI:	Provider Name:					
Provider Phone:		Provider Fax:				
Prescriber Information						
Prescriber NPI:	Presc	riber Name:				
Prescriber Phone:	Prescribe	r Fax:	Specialty:			
Criteria						
For Initial Authorization 1. Please indicate the of Breast Cancer A. Does member Yes No	diagnosis and inform <u>er ha</u> ve Human Epiderr		/pe 2 (HER2)-positive disease?			

- B. Will Phesgo[™] be used as <u>neoadjuvant</u> treatment for locally advanced, inflammatory, or early stage breast cancer? Yes D No
- C. Will Phesgo[™] be used as adjuvant treatment for early stage breast cancer? Yes No
- D. Will Phesgo[™] be used in combination with docetaxel for metastatic disease? Yes ____ No

□ If answer is none of the above, please indicate diagnosis:

Additional Information:

For Continued Authorization:

- 1. Date of last dose:
- 2. Does member have any evidence of progressive disease while on Phesgo[™] ? Yes ____ No

3. Has the member experienced adverse drug reactions related to Phesgo[™] therapy? Yes If yes, please specify adverse reactions:

Prescriber Signature:_

Date:

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of mv knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.